Pustular psoriasis is a severe inflammatory skin condition marked by the sudden eruption of sterile, pus-filled blisters over red, painful skin, often accompanied by fever and systemic illness. Unlike the far more common plaque psoriasis, which produces raised, scaly patches and is driven primarily by a different branch of the immune system, pustular psoriasis involves runaway activation of the body’s innate immune defenses and a specific inflammatory signaling chain centered on a family of proteins called interleukin-36. The distinction matters because it changes how the disease behaves, who it affects, and which treatments actually work.
Not Just Another Kind of Psoriasis
Many people assume pustular psoriasis is simply a more intense version of the plaque psoriasis that affects roughly two to three percent of the global population. That assumption is increasingly outdated. Expert consensus and growing genetic evidence now treat generalized pustular psoriasis (GPP) as a fundamentally distinct disease, not merely a subtype of ordinary psoriasis.1PubMed. Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion The two diseases look different under a microscope, arise from different immune pathways, and respond to different therapies.
Plaque psoriasis is driven largely by the adaptive immune system, with a central role for the cytokine IL-17. Pustular psoriasis, by contrast, stems from dysregulation of the innate immune system, where overactive IL-36 signaling triggers inflammatory responses in skin cells and floods the affected area with neutrophils, a type of white blood cell.2PubMed Central. Pathophysiology of Generalized Pustular Psoriasis Those masses of neutrophils are what form the visible pustules. Some people with GPP also have plaque psoriasis, which muddies the picture, but you can develop GPP with no history of plaque disease at all.
Generalized Versus Localized Forms
Pustular psoriasis comes in several forms, and the most important distinction is between generalized and localized disease. Generalized pustular psoriasis involves widespread eruptions that can cover large areas of the body, often accompanied by fever, fatigue, elevated inflammatory markers, and the kind of systemic illness that can land you in the hospital.3Dermatologica Sinica. Phenotypic differences in clinical manifestations of generalized pustular psoriasis and severe plaque psoriasis in tropical Taiwan Flares can appear with or without a clear trigger, and the disease tends to follow an unpredictable relapsing course.
Localized forms are more common but affect only specific body sites. The two main ones are palmoplantar pustulosis (PPP), which targets the palms and soles, and acrodermatitis continua of Hallopeau (ACH), which affects the fingertips and nail beds. A large European study comparing these two found that PPP was more strongly associated with female sex, smoking, and higher body mass index, while ACH was more likely to involve peripheral joint inflammation.4PubMed Central. Palmoplantar pustulosis and acrodermatitis continua of Hallopeau: demographic and clinical comparative study in a large multicentre cohort In that study, the typical age of onset for both was in the mid-forties. Both localized forms carried a roughly equal chance of coexisting with another type of psoriasis.
Despite grouping them together under “pustular psoriasis,” these subtypes differ enough in their clinical behavior, prognosis, and treatment response that researchers and clinicians increasingly treat them as related but distinct entities.
The Genetic Roots
One of the strongest pieces of evidence that GPP is its own disease came from a landmark genetic study published in the New England Journal of Medicine, which identified mutations in a gene called IL36RN on chromosome 2. That gene encodes a protein that normally acts as a brake on IL-36 signaling. When the brake is faulty, IL-36 inflammatory activity runs unchecked.5PubMed. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis
Since that discovery, researchers have found several more genes linked to GPP. Variants in CARD14, AP1S3, MPO, SERPINA3, BTN3A3, and MEFV have all been identified, and they share a common theme: each contributes to excessive activation of innate immune pathways and resulting skin inflammation.6PubMed Central. Updated genetic background of generalized pustular psoriasis as an autoinflammatory keratinization disease Not every patient with GPP carries one of these mutations, which means additional genetic contributors likely remain undiscovered. But the pattern is consistent: GPP behaves as an autoinflammatory disease of the skin, where genetic predisposition primes the immune system to overreact in the epidermis.
How the IL-36 Pathway Drives Flares
The immune cascade behind a GPP flare is now reasonably well mapped. Keratinocytes, the main cells of the outer skin layer, produce IL-36 cytokines in excess. Those cytokines kick off a self-amplifying loop: they activate nearby keratinocytes to release more IL-36, along with chemokines that summon neutrophils from the bloodstream.7PubMed Central. The role of the interleukin-36 axis in generalized pustular psoriasis: a review of the mechanism of action of spesolimab The neutrophils pile up in the upper layers of the skin, forming the characteristic sterile pustules. “Sterile” is the important word here: despite looking infected, the pustules contain no bacteria. The pus is pure inflammation.
This IL-36-driven loop sets GPP apart from plaque psoriasis at a fundamental level. In plaque disease, the adaptive immune system’s T cells and IL-17 signaling dominate. In GPP, the innate immune response predominates, sustained by the action of IL-36 cytokines on keratinocytes.8Trends in Immunology. Unraveling the immunological and genetic underpinnings of generalized pustular psoriasis This distinction has become the basis for a new generation of targeted treatments.
What Triggers a Flare
GPP flares can seemingly appear out of nowhere, but several known triggers are well documented. Withdrawal of systemic corticosteroids is one of the most recognized, and it is one reason dermatologists are cautious about prescribing oral steroids for psoriasis patients. Infections, psychological stress, pregnancy, and menstruation are also established triggers.9PubMed Central. Clinical Course and Characteristics of Generalized Pustular Psoriasis
A study from Taiwan found that patients with GPP were more likely than those with severe plaque psoriasis to have drug allergies, particularly to certain antibiotics and anti-inflammatory medications, and to present with fever, leukocytosis (high white blood cell count), and elevated C-reactive protein during flares.10Dermatologica Sinica. Phenotypic differences in clinical manifestations of generalized pustular psoriasis and severe plaque psoriasis in tropical Taiwan The clinical picture often resembles an acute systemic illness, and patients frequently require hospitalization for extended stays.
Pustular Psoriasis in Pregnancy
One particularly dramatic variant occurs during pregnancy. Historically called impetigo herpetiformis, despite having nothing to do with herpes or impetigo, this form is now recognized as pustular psoriasis of pregnancy. It typically appears in the third trimester and resolves after delivery.11PubMed Central. Pustular psoriasis of pregnancy (impetigo herpetiformis)–case report The clinical and microscopic appearance is consistent with GPP, and many experts now consider it a pregnancy-triggered form of the same disease.
The condition can carry significant risks for both mother and baby, including complications that extend beyond the skin.12PubMed Central. Impetigo Herpetiformis: Review of Pathogenesis, Complication, and Treatment Treatment is complicated by the need to avoid medications that could harm the developing fetus, which rules out most of the standard systemic drugs. Close collaboration between dermatology and obstetrics is essential, and the condition tends to recur in subsequent pregnancies.
When the Disease Goes Beyond the Skin
GPP is not just a skin problem. During severe flares, the systemic inflammatory response can affect multiple organ systems. The cardiovascular system, liver, kidneys, and lungs can all be involved, and GPP has been linked to increased rates of anemia, depression, anxiety, and arthritis.13PubMed Central. Generalized Pustular Psoriasis and Systemic Organ Dysfunctions Left untreated, severe flares carry real danger: sepsis and cardiovascular failure are among the most serious potential complications.14PubMed Central. Generalized Pustular Psoriasis: A Review on Clinical Characteristics, Diagnosis, and Treatment
This systemic involvement is part of what makes GPP so much more burdensome than its rarity might suggest. It isn’t just painful, itchy, and visible; it creates a whole-body inflammatory state that requires monitoring well beyond the skin surface.
Telling It Apart From Drug Reactions
One of the trickiest diagnostic challenges with pustular psoriasis is distinguishing it from acute generalized exanthematous pustulosis (AGEP), a drug-reaction condition that can look almost identical. Both produce widespread sterile pustules over red skin. The timing matters: AGEP almost always follows a new medication, typically antibiotics, and resolves when the drug is stopped. Features that point toward pustular psoriasis include a prior history of psoriasis and the presence of scaling plaques underneath the pustules. Under the microscope, AGEP is more likely to show eosinophilic spongiosis and certain other features in the dermal tissue.15PubMed Central. Pustular Psoriasis and Acute Generalized Exanthematous Pustulosis
Getting this distinction right matters for treatment. AGEP resolves with drug withdrawal and supportive care, while GPP demands active immune-modulating therapy. A misdiagnosis in either direction can lead to unnecessary immunosuppression or inadequate treatment of a potentially life-threatening condition.
Conventional Treatment Options
Before the advent of targeted biologics, treatment for GPP relied on broadly immunosuppressive drugs, and the evidence base was thin. Cyclosporine, a calcineurin inhibitor, has been one of the more commonly used first-line agents for acute flares. It works by suppressing the immune system, and some patients respond, but recurrence after stopping the drug is common, and long-term use is limited by the risk of kidney damage, high blood pressure, and infections.16PubMed Central. Treatment Options and Goals for Patients with Generalized Pustular Psoriasis
Retinoids like acitretin represent the main non-immunosuppressive option. In a small study of 15 patients with pustular psoriasis, acitretin prevented new pustule formation within about three days and cleared most skin lesions within four to six weeks, but relapses were common after stopping the drug.17PubMed Central. Treatment Options and Goals for Patients with Generalized Pustular Psoriasis Retinoids also carry their own significant drawbacks: they cause birth defects and must be avoided in pregnancy, and can cause liver damage, bone and mucous membrane toxicity, and elevated cholesterol. In children with GPP, cyclosporine and acitretin are used in similar fashion, though dosing must be carefully adjusted, and frequent relapses requiring dose escalation remain a challenge.18Clinical Case Reports. Juvenile Generalized Pustular Psoriasis: Management in Children-A Case Series
The overall picture with conventional therapies has been one of incomplete responses, frequent relapses, and treatment-limiting side effects. There has been a genuine unmet need for drugs that target the actual disease mechanism rather than broadly suppressing the immune system.
Spesolimab and the IL-36 Receptor Blockade
The understanding that IL-36 signaling sits at the center of GPP opened the door to a precision therapy. Spesolimab is a humanized antibody that blocks the IL-36 receptor, directly interrupting the inflammatory loop that causes pustule formation. It became the first biologic approved specifically for GPP flares, receiving approval in the European Union in late 2022.19PubMed Central. Therapeutic Potential of Spesolimab-Sbzo in the Management of Generalized Pustular Psoriasis Flares in Adults: Evidence to Date
The pivotal trial compared a single intravenous dose of spesolimab to placebo in patients experiencing an active GPP flare. By the end of the first week, about 54% of patients receiving spesolimab had complete clearance of pustules, compared to 6% on placebo. Roughly 43% of the spesolimab group achieved near-clear or clear skin overall, versus 11% in the placebo group.20PubMed. Trial of Spesolimab for Generalized Pustular Psoriasis Those numbers may not sound overwhelming in absolute terms, but for a disease where flares can be life-threatening and prior treatments had essentially no rigorous trial data, the results were transformative.
Molecular analysis from the same trial showed that spesolimab reduced not just the visible disease but the underlying biological fire. Expression of IL-36 genes and genes responsible for neutrophil recruitment dropped in skin biopsies, and blood levels of key inflammatory markers like IL-17, IL-8, and IL-6 stayed reduced for up to twelve weeks after a single dose.21PubMed Central. Spesolimab Reduces Inflammation in Generalized Pustular Psoriasis: Molecular Characterization of Flare Treatment in EFFISAYIL 1 Access remains an issue, though, given the drug’s high cost and the need for intravenous administration during an acute flare.22PubMed Central. Generalized Pustular Psoriasis: Current Treatment and Innovative Therapies
IL-17 and IL-23 Inhibitors as Alternatives
Because some patients with GPP also have features of plaque psoriasis, biologics targeting IL-17 and IL-23, which are standard treatments for plaque disease, have also been used off-label for pustular psoriasis. A retrospective multicenter study compared the two drug classes head-to-head in patients with pustular and erythrodermic psoriasis. Among the pustular psoriasis patients, those receiving IL-17 inhibitors achieved substantially higher rates of near-complete and complete skin clearance than those on IL-23 inhibitors at twelve weeks, and the gap widened by twenty-four weeks, when about 74% of patients on IL-17 inhibitors met a high response threshold compared to 25% on IL-23 inhibitors.23PubMed Central. Interleukin-17 vs. Interleukin-23 Inhibitors in Pustular and Erythrodermic Psoriasis: A Retrospective, Multicentre Cohort Study
These findings suggest that IL-17 inhibitors, in particular, can be effective in pustular psoriasis, which makes biological sense given that IL-17 operates downstream of some of the same inflammatory cascades that IL-36 activates. The evidence here is retrospective rather than from a randomized trial, so the conclusions are less definitive. Still, for patients who cannot access spesolimab or need a maintenance option between flares, IL-17 inhibitors represent a reasonable alternative supported by real-world data.
Living With GPP Between Flares
A common misconception about GPP is that the disease only matters during acute flares and that patients are fine in between. Survey and interview data tell a different story. Most patients report chronic symptoms even outside of flares, including persistent itchy and dry skin and joint pain. In one global assessment, 80% of interviewed patients described ongoing symptoms, and 60% said chronic symptoms significantly affected their daily activities.24PubMed Central. A Global Assessment of Patient Experience and Quality of Life in Generalized Pustular Psoriasis: Results from Interviews and Online Surveys
Quality-of-life scores bear this out. A systematic review found that mean scores on a widely used dermatology quality-of-life index ranged from moderate to very large impact across studies, and that people with GPP consistently reported worse quality of life than people with plaque psoriasis, particularly in terms of itch, pain, and fatigue.25PubMed. Health-related quality of life in patients with generalized pustular psoriasis: A systematic literature review Anxiety and depression were reported regularly, both during and between flares, and the disease’s unpredictability itself becomes a source of psychological distress.26PubMed Central. Clinical and Disease Burden of Patients with Generalized Pustular Psoriasis: A Review of Real-World Evidence If you have GPP, the disease does not go away when the pustules do. The fear that a flare could strike at any time, combined with chronic low-level symptoms, creates a persistent burden that standard measures of disease severity, which focus on what the skin looks like at one point in time, tend to undercount.
What a Skin Biopsy Shows
If you are being evaluated for pustular psoriasis, a skin biopsy can help confirm the diagnosis and rule out mimics. Under the microscope, pustular psoriasis shows collections of neutrophils in the upper epidermis, forming structures called spongiform pustules of Kogoj, along with characteristic features of psoriasiform skin, including elongated and fused rete ridges, thinning of the granular layer, and dilated capillaries in the upper dermis.27PubMed Central. The histopathological landscape of the major psoriasiform dermatoses These findings help clinicians distinguish pustular psoriasis from conditions like AGEP and other neutrophilic skin diseases. The biopsy is especially useful when the clinical picture is ambiguous, as it often is when a patient presents for the first time with no prior history of psoriasis.